A pragmatic protocol for I-131 rhTSH-stimulated ablation therapy in patients with renal failure

Clinical Nuclear Medicine

Volumn 31, Issue 8, 2006, Pages 454-457

  Driedger, A A ^a,b   Quirk, S ^a   McDonald, T J ^a   Ledger, S ^a   Gray, D ^a   Wall, W ^a   Yoo, J ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b Nuclear Medicine   (Canada)

Author keywords

Ablation; Euthyroid; Hypothyroidism; Renal failure; Thyroid carcinoma

Indexed keywords

IODINE 131; LEVOTHYROXINE; RECOMBINANT THYROTROPIN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BONE MARROW DISEASE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURGERY; CASE REPORT; CLINICAL PROTOCOL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DEEP VEIN THROMBOSIS; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DOSE CALCULATION; DRUG CLEARANCE; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; KIDNEY FAILURE; MALE; MEASUREMENT; MINIMAL RESIDUAL DISEASE; MORBIDITY; PLASMA CLEARANCE; RADIATION DOSE; RADIATION INJURY; RISK REDUCTION; THYROID CARCINOMA; THYROIDECTOMY;

ADULT; AGED; CLINICAL PROTOCOLS; DIABETES MELLITUS, TYPE 1; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; IODINE RADIOISOTOPES; KIDNEY FAILURE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RADIOMETRY; RADIOPHARMACEUTICALS; RECOMBINANT PROTEINS; RENAL DIALYSIS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; THYROXINE; WEGENER GRANULOMATOSIS;

EID: 33748145959     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rlu.0000227013.36421.ce     Document Type: Article

References (19)

1. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-1463.
2. Chow SM, Law SC, Mendenhall WM, et al. Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. Int J Radiat Oncol Biol Phys. 2002;52:784-795.
3. Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid. 1998;8:737-744.
4. Ringel MD, Ladenson PW. Controversies in the follow-up and management of well-differentiated thyroid cancer. Endocrine-Related Cancer. 2004;11:97-116.
5. Bal C, Padhy AK, Jana S, et al. Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer. 1997;79:190-191.
6. Beierwaltes WH, Rabbini R, Dmuchowski C, et al. An analysis of 'ablation of thyroid remnants' with I131 in 511 patients from 1947-1984: experience at the University of Michigan. J Nucl Med. 1984;25:1287-1293.
7. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 1983;309:937-941.
8. Maxon HR. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med. 1999;43:313-323.
9. Cormack J, Shearer J. Calculation of radiation exposures from patients to whom radioactive materials have been administered. Phys Med Biol. 1998;43:501-516.
10. North DL, Shearer DR, Hennessey JV, et al. Effective half-life of I131 in thyroid cancer patients. Health Physics. 2001;81:325-329.
11. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:878-884.
12. Culpepper RM, Hirsch JI, Fratkin MJ. Clearance of I131 by hemodialysis. Clin Nephrol. 1992;38:110-114.
13. Daumerie C, Vynckier S, Caussin J, et al. Radioiodine treatment of thyroid carcinoma in patients on maintenance hemodialysis. Thyroid. 1996;6:301-304.
14. Mello AM, Isaacs R, Petersen J, et al. Management of thyroid papillary carcinoma with radioiodine in a patient with end stage renal disease on hemodialysis. Clin Nucl Med. 1994;19:776-781.
15. Kaptein EM, Levenson H, Siegel ME, et al. Radioiodine dosimetry in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis therapy. J Clin Endocrinol Metab. 2000;85:3058-3064.
16. Toubert M-E, Michel C, Metivier F, et al. Iodine-131 ablation therapy for a patient receiving peritoneal dialysis. Clin Nucl Med. 2001;26:302-305.
17. Jawa A, Pendergrass M. A Case of Recombinant TSH for the Treatment of Papillary Thyroid Cancer in a Patient With End Stage Renal Disease. American Thyroid Association; Palm Beach; Sept 16-21, 2003.
18. Magne N, Magne J, Bracco J, et al. Disposition of radioiodine I131 for thyroid carcinoma in a patient with severely impaired renal function on chronic dialysis: a care report. Jpn J Clin Oncol. 2002;32:202-205.
19. Sinsakul M, Ali A. Radioactive I131 use in end-stage renal disease: nightmare or nuisance? Semin Dial. 2004;17:53-56.